PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition
暂无分享,去创建一个
R. Neve | D. Aust | C. Pilarsky | F. Gnad | Yulei N. Wang | E. Jaffee | M. Belvin | R. Grützmann | A. Jubb | W. Forrest | K. Hoeflich | H. Koeppen | L. Friedman | P. Haverty | Yibing Yan | M. Merchant | Wei Zhou | R. Desai | R. Raja | K. Totpal | Peter M. Haverty | L. Fu | K. Lyle | C. Ong | Q. Xiao | M. Romero | A. De Jesus-Acosta | Qinghua Song | L. Zheng | Rupal H Desai
[1] T. Jin,et al. p21-Activated protein kinases and their emerging roles in glucose homeostasis. , 2014, American journal of physiology. Endocrinology and metabolism.
[2] I. Wistuba,et al. Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit , 2014, Clinical Cancer Research.
[3] R. Govindan,et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. V. Vande Woude,et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.
[5] Luis E. Arias-Romero,et al. Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells. , 2013, Cancer research.
[6] A. Harris,et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. , 2013, Journal of the National Cancer Institute.
[7] Thomas D. Wu,et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.
[8] A. Jubb,et al. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. , 2012, Cancer research.
[9] W. Birchmeier,et al. Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.
[10] D. Wazer,et al. New tools and novel approaches in treating locally advanced pancreatic adenocarcinoma. , 2012, JOP : Journal of the pancreas.
[11] Jane Fridlyand,et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.
[12] Da-Qiang Li,et al. Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations , 2012, Clinical Cancer Research.
[13] M. Belvin,et al. Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes , 2012, PloS one.
[14] G. Kristiansen,et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma , 2012, Nature.
[15] J. Field,et al. PAK signaling in cancer , 2012, Cellular logistics.
[16] T. Welling,et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. , 2011, Gastroenterology.
[17] P. Hegde,et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. , 2011, Cancer discovery.
[18] J. Chernoff,et al. Inhibition or Ablation of p21-activated Kinase (PAK1) Disrupts Glucose Homeostatic Mechanisms in Vivo* , 2011, The Journal of Biological Chemistry.
[19] Todd R. Golub,et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling , 2011, Oncogene.
[20] A. Maitra,et al. Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer , 2011, PloS one.
[21] A. Harris,et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells , 2011, Proceedings of the National Academy of Sciences.
[22] J. Reis-Filho,et al. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation , 2011, Modern Pathology.
[23] K. Lillemoe,et al. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.
[24] G. Shapiro,et al. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. , 2010, Current opinion in investigational drugs.
[25] J. Masters,et al. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion , 2010, Journal of Cell Science.
[26] A. Ridley,et al. PAK1 and PAK2 have different roles in HGF-induced morphological responses. , 2009, Cellular signalling.
[27] Alison P. Klein,et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] G. Baldwin,et al. PAK1 interacts with beta-catenin and is required for the regulation of the beta-catenin signalling pathway by gastrins. , 2008, Biochimica et biophysica acta.
[29] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[30] Gary Box,et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.
[31] S. Deacon,et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. , 2008, Chemistry & biology.
[32] I. Kasman,et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.
[33] C. Liang,et al. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.
[34] M. Westphal,et al. A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.
[35] R Smits,et al. Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia , 2006, Oncogene.
[36] D. Pardoll,et al. Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. , 2006, Cancer research.
[37] E. Rosen,et al. Role of NF-κB signaling in hepatocyte growth factor/scatter factor-mediated cell protection , 2005, Oncogene.
[38] S. Batra,et al. Neural Invasion in the Staging of Pancreatic Cancer , 2003, Pancreas.
[39] K. Herzig,et al. Expression of hepatocyte growth factor, keratinocyte growth factor and their receptors in experimental chronic pancreatitis , 2001, European journal of clinical investigation.
[40] K. Kaibuchi,et al. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. , 2000, Molecular biology of the cell.
[41] Richard A. Szucs,et al. TNM Classification of Malignant Tumors. 5th ed , 1998 .
[42] S. Ohwada,et al. Growth dependency of a new human pancreatic cancer cell line, YAPC, on autocrine interleukin‐1α stimulation , 1998, International journal of cancer.
[43] R. Poulsom,et al. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. , 1995, Cancer research.
[44] Mark Merchant,et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. , 2012, Cancer research.
[45] A. Whale,et al. Signalling to cancer cell invasion through PAK family kinases. , 2011, Frontiers in bioscience.
[46] D. Pardoll,et al. Synergistic Effect of a Granulocyte-Macrophage Colony-Stimulating Factor–Transduced Tumor Vaccine and Systemic Interleukin-2 in the Treatment of Murine Colorectal Cancer Hepatic Metastases , 2003, Annals of Surgical Oncology.